Daily non-political popular news in brief.

Protecting HIV patients from Hepatitis B virus

As it is not quite clear how HIV patients that don’t respond to the HBV vaccine should be managed, new research from the University of Alberta has evaluated the immune response of HBV vaccine given intradermally (into the skin) in HIV-infected individuals who failed to respond to two cycles of HBV vaccine given intramuscularly (into the muscle).

Read more »

Keywords: protecting, hiv, patients, hepatitis, virus, patient, hepatiti, viru

« Previous | Next »

Similar news on "Protecting HIV patients from Hepatitis B virus":

1. Widely used hepatitis B drug spurs HIV drug resistance
   02-28-2007 · EurekAlert!
   A Johns Hopkins study has proven false established medical practice that an antiretroviral drug widely used to treat hepatitis B liver infections was safe to use on its own in patients co-infected with HIV. Their findings demonstrate that treatment with entecavir leads to cross-resistance to other antiviral drugs used to treat the AIDS virus.
   Similar news · Read more »
   
2. Study finds limited options for backup HIV treatment in some developing countries
   01-08-2007 · EurekAlert!
   Thai researchers have discovered that patients who fail treatment with a commonly used, inexpensive, first-line antiretroviral therapy (ART) are also usually resistant to other, similar drugs, leaving progressively fewer options for replacement therapies. Since catching treatment failure early is key to preventing further resistance, this research, published in the February 1 issue of Clinical Infectious Diseases also argues for greater access in the developing world to tests that detect when the amount of virus in a patient's blood is increasing.
   Similar news · Read more »
   
3. 24-week course of interferon-alpha therapy prolongs survival in patients hepatitis C virus
   11-02-2007 · EurekAlert!
   A group at Hiroshima University Hospital performed a matched historical controlled study on whether a 24-week course of interferon-alpha therapy, after curative treatment for primary hepatocellular carcinoma associated with hepatitis C virus, could influence tumor recurrence, patient survival, and liver function. Patients with sustained virological responses had reduced recurrence, prolonged survival and a preserved liver function. The group also determined that viral eradication was the most important factor in such patients.
   Similar news · Read more »
   
4. Rare case of dental patient-to-patient hepatitis B virus transmission recorded
   04-03-2007 · EurekAlert!
   Researchers have documented a case of hepatitis B virus (HBV) transmission between two patients at a dentist's office in the United States. While this kind of infection is exceedingly rare, universal vaccination against the virus would likely have prevented both cases, according to the authors of the case report and an accompanying commentary. Both appear in the May 1 issue of the Journal of Infectious Diseases, now available online.
   Similar news · Read more »
   
5. MGH study examines impact of infection with both HIV and hepatitis C virus
   12-11-2006 · EurekAlert!
   In a report in the December issue of PLOS Medicine, a group of researchers from the Partners AIDS Research Center at Massachusetts General Hospital report one of the first studies of how HIV infection impacts immune system functions involved with hepatitis C virus control. Their findings suggest that beginning antiretroviral therapy earlier than is generally recommended may help preserve HCV control in patients infected with both viruses.
   Similar news · Read more »
   
6. Hepatitis B drug can compromise HIV treatment
   06-20-2007 · EurekAlert!
   Treating hepatitis B patients with the drug entecavir can cause those who are also infected with HIV to become resistant to two of the most important drugs in the anti-HIV arsenal. In findings published in the New England Journal of Medicine, researchers reported that a patient infected with both hepatitis B and HIV who was treated with entecavir developed a mutant strain of HIV that is resistant to the antiviral drugs lamivudine and emtricitabine.
   Similar news · Read more »
   
7. One-fourth of HIV patients believe their doctors stigmatize them
   08-31-2007 · EurekAlert!
   Physicians might want to be extra careful about how they treat HIV-infected patients —not just in the clinical sense but in the way they behave toward them. Even the perception that physicians are stigmatizing patients for carrying the virus that causes AIDS can discourage these individuals from seeking proper medical care, according to a new UCLA study.
   Similar news · Read more »
   
8. Researchers Refocus Studies On Patients With HIV, Hepatitis
   10-12-2006 · ScienceDaily
   As HIV patients live longer thanks to advanced therapies, researchers are looking for better ways to treat accompanying maladies such as hepatitis that traditionally were not emphasized.
   Similar news · Read more »
   
9. LIAI scientists make important finding on cytomegalovirus transmission
   05-10-2007 · EurekAlert!
   Researchers at the La Jolla Institute for Allergy & Immunology have shown that cytomegalovirus (CMV) in the salivary glands can be reduced -- and in some cases eliminated -- through the use of antibodies to enhance the disease-fighting power of the immune system. The research team's findings, based on controlled laboratory studies of mice, may also have implications for other chronic virus infections, such as hepatitis and HIV, the virus that causes AIDS.
   Similar news · Read more »
   
10. As dialysis becomes a target of cost control, doctor-patient relationship is key
    06-13-2007 · EurekAlert!
    As medical, economic, and policy trends converge to alter the way dialysis care is organized and financed, protecting the unique relationship between dialysis patients and the kidney specialists who direct their care is a top priority, according to a special feature in the July Journal of the American Society of Nephrology.
    Similar news · Read more »